IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, prospective phase II study to evaluate the efficacy and
safety of a novel combination regimen for relapsed/refractory PCNSL. Specifically, ibrutinib
will be administered in combination with ifosfamide, etoposide and rituximab (IBER) as a
salvage chemotherapy, which is followed by maintenance ibrutinib monotherapy of fixed
duration.